Neurovalens is pioneering non-invasive neurostimulation devices that leverage the power of electrical modulation to address global health challenges.
Neurovalens has created a world-leading nerve stimulation technology to tackle some of humanity’s most pressing public health concerns. Its devices employ electrical stimulation of the vestibular nerve to target key sites on the body which can enhance treatments for a variety of diseases. The company has created several products in its MODIUS portfolio, covering Insomnia, Anxiety, Obesity, Diabetes, PTSD and Depression. Neurovalens achieved FDA 510k approval for several of its products in 2024, allowing them to be marketed in the USA to patients.
The company was founded by Jason McKeown (CEO) based on many years of research at the University of California, San Diego.
